9th Aug 2019 08:29
(Alliance News) - AstraZeneca PLC on Friday said drug Tagrisso significantly improved overall survival during its phase 3 Flaura trial in non-small cell lung cancer patients.
The trial involved patients with locally-advanced or metastatic lung cancer and epidermal growth factor receptor mutations. It found a "statistically-significant and clinically-meaningful improvement" in overall survival compared to previous standard-of-care treatments.
Overall survival was the secondary endpoint of the study. Flaura met its primary endpoint back in July 2017 when is demonstrated an improvement in progression-free survival - time lived with no disease progression or death.
Drug major Astra said Tagrisso's safety and tolerability during the study was "consistent with its established profile".
Jose Baselga, executive vice president of Oncology Research & Development at Astra said: "Today's positive results show that Tagrisso provides an unprecedented survival outcome versus previous standard-of-care epidermal growth factor receptor tyrosine kinase inhibitors, reaffirming Tagrisso as the 1st-line standard-of-care for EGFR-mutated metastatic non-small cell lung cancer."
At present, Tagrisso has been approves in 74 countries - including Japan, the US, and the EU - as a first line treatment for epidermal growth factor receptor mutated metastatic non-small cell lung cancer.
Shares in AstraZeneca were up 0.2% at 7,242.00 pence on Friday morning in London.
Related Shares:
Astrazeneca